Literature DB >> 33718107

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects.

Remy Thomas1, Ghaneya Al-Khadairi1,2, Julie Decock1,2.   

Abstract

Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient's own immune cells to kill tumors and revolutionizing cancer treatment in a variety of cancers. Although breast cancer was historically believed to be immunologically silent, treatment with immune checkpoint inhibitors has been shown to induce modest responses in metastatic breast cancer. Given the inherent heterogeneity of breast tumors, this raised the question whether certain breast tumors might benefit more from immune-based interventions and which cancer cell-intrinsic and/or microenvironmental factors define the likelihood of inducing a potent and durable anti-tumor immune response. In this review, we will focus on triple negative breast cancer as immunogenic breast cancer subtype, and specifically discuss the relevance of tumor mutational burden, the plethora and diversity of tumor infiltrating immune cells in addition to the immunoscore, the presence of immune checkpoint expression, and the microbiome in defining immune checkpoint blockade response. We will highlight the current immune checkpoint inhibitor treatment options, either as monotherapy or in combination with standard-of-care treatment modalities such as chemotherapy and targeted therapy. In addition, we will look into the potential of immunotherapy-based combination strategies using immune checkpoint inhibitors to enhance both innate and adaptive immune responses, or to establish a more immune favorable environment for cancer vaccines. Finally, the review will address the need for unambiguous predictive biomarkers as one of the main challenges of immune checkpoint blockade. To conclude, the potential of immune checkpoint blockade for triple negative breast cancer treatment could be enhanced by exploration of aforementioned factors and treatment strategies thereby providing promising future prospects.
Copyright © 2021 Thomas, Al-Khadairi and Decock.

Entities:  

Keywords:  combination therapy; immune checkpoint blockade; predictive biomarkers; programmed death ligand-1 (PD-L1); programmed death-1 (PD-1); triple negative breast cancer; tumor infiltrating lymphocytes; tumor mutational burden

Year:  2021        PMID: 33718107      PMCID: PMC7947906          DOI: 10.3389/fonc.2020.600573

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  160 in total

Review 1.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 3.  Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers.

Authors:  Jennifer L McQuade; Gabriel O Ologun; Reetakshi Arora; Jennifer A Wargo
Journal:  Curr Oncol Rep       Date:  2020-06-24       Impact factor: 5.075

4.  Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.

Authors:  Emily S Reisenbichler; Gang Han; Andrew Bellizzi; Veerle Bossuyt; Jane Brock; Kimberly Cole; Oluwole Fadare; Omar Hameed; Krisztina Hanley; Beth T Harrison; M Gabriela Kuba; Amy Ly; Dylan Miller; Mirna Podoll; Anja C Roden; Kamaljeet Singh; Mary Ann Sanders; Shi Wei; Hannah Wen; Vasiliki Pelekanou; Vesal Yaghoobi; Fahad Ahmed; Lajos Pusztai; David L Rimm
Journal:  Mod Pathol       Date:  2020-04-16       Impact factor: 7.842

5.  Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.

Authors:  Rachael M Zemek; Emma De Jong; Wee Loong Chin; Iona S Schuster; Vanessa S Fear; Thomas H Casey; Cath Forbes; Sarah J Dart; Connull Leslie; Ayham Zaitouny; Michael Small; Louis Boon; Alistair R R Forrest; Daithi O Muiri; Mariapia A Degli-Esposti; Michael J Millward; Anna K Nowak; Timo Lassmann; Anthony Bosco; Richard A Lake; W Joost Lesterhuis
Journal:  Sci Transl Med       Date:  2019-07-17       Impact factor: 17.956

6.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

7.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

Authors:  Makoto Miyara; Yumiko Yoshioka; Akihiko Kitoh; Tomoko Shima; Kajsa Wing; Akira Niwa; Christophe Parizot; Cécile Taflin; Toshio Heike; Dominique Valeyre; Alexis Mathian; Tatsutoshi Nakahata; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono; Zahir Amoura; Guy Gorochov; Shimon Sakaguchi
Journal:  Immunity       Date:  2009-05-21       Impact factor: 31.745

8.  Structure, function and diversity of the healthy human microbiome.

Authors: 
Journal:  Nature       Date:  2012-06-13       Impact factor: 49.962

Review 9.  Immune checkpoint inhibitors: recent progress and potential biomarkers.

Authors:  Pramod Darvin; Salman M Toor; Varun Sasidharan Nair; Eyad Elkord
Journal:  Exp Mol Med       Date:  2018-12-13       Impact factor: 8.718

Review 10.  Immunotherapy: A Challenge of Breast Cancer Treatment.

Authors:  Marilina García-Aranda; Maximino Redondo
Journal:  Cancers (Basel)       Date:  2019-11-20       Impact factor: 6.639

View more
  29 in total

Review 1.  Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).

Authors:  Aiswarya Chaudhuri; Dulla Naveen Kumar; Deepa Dehari; Sanjay Singh; Pradeep Kumar; Pradeep Kumar Bolla; Dinesh Kumar; Ashish Kumar Agrawal
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

Review 2.  Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.

Authors:  Chenyi Luo; Peipei Wang; Siqi He; Jingjing Zhu; Yuanyuan Shi; Jianxun Wang
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

3.  Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy.

Authors:  Ethan Shelkey; David Oommen; Elizabeth R Stirling; David R Soto-Pantoja; Katherine L Cook; Yong Lu; Konstantinos I Votanopoulos; Shay Soker
Journal:  Sci Rep       Date:  2022-06-15       Impact factor: 4.996

4.  FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.

Authors:  Yushen Wu; Ziying Yi; Jie Li; Yuxian Wei; Rui Feng; Jiazhou Liu; Jiefeng Huang; Yuru Chen; Xiaoyu Wang; Jiazheng Sun; Xuedong Yin; Yunhai Li; Jingyuan Wan; Li Zhang; Jing Huang; Huimin Du; Xiaoyi Wang; Qin Li; Guosheng Ren; Hongzhong Li
Journal:  Theranostics       Date:  2022-05-27       Impact factor: 11.600

5.  Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs.

Authors:  André E Nel; Kuo-Ching Mei; Yu-Pei Liao; Xiangsheng Liu
Journal:  ACS Nano       Date:  2022-03-29       Impact factor: 18.027

Review 6.  PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.

Authors:  Linjie Luo; Khandan Keyomarsi
Journal:  Expert Opin Investig Drugs       Date:  2022-05-03       Impact factor: 6.498

7.  Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.

Authors:  Quentin Klopfenstein; Valentin Derangère; Laurent Arnould; Marion Thibaudin; Emeric Limagne; Francois Ghiringhelli; Caroline Truntzer; Sylvain Ladoire
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

Review 8.  Quantitative proteomics characterization of cancer biomarkers and treatment.

Authors:  Xiao-Li Yang; Yi Shi; Dan-Dan Zhang; Rui Xin; Jing Deng; Ting-Miao Wu; Hui-Min Wang; Pei-Yao Wang; Ji-Bin Liu; Wen Li; Yu-Shui Ma; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2021-04-20       Impact factor: 7.200

Review 9.  Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies.

Authors:  Anindita Chakrabarty; Shayantani Chakraborty; Ranjini Bhattacharya; Goutam Chowdhury
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

10.  O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.

Authors:  Jing-Yan Cheng; Jung-Tung Hung; Juway Lin; Fei-Yun Lo; Jing-Rong Huang; Shih-Pin Chiou; Ya-Hui Wang; Ruey-Jen Lin; Jen-Chine Wu; John Yu; Alice L Yu
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.